Robert R. Jenq
Assistant Attending, Bone Marrow Transplant
Lab Phone:
646-888-2317
Education:
Oregon Health and Science University School of Medicine, Portland, Oregon
My career aim is to develop and evaluate strategies that improve outcomes after hematopoietic stem cell transplantation (HSCT), in particular by augmenting graft-versus-tumor (GVT) to reduce the rates of malignant relapse and alleviating graft-versus-host disease (GVHD). To this goal, I have studied therapies that modulate alloreactive T cells in GVT and GVHD, using mouse models of HSCT.
To develop strategies of augmenting anti-tumor immunity following HSCT, I have focused in particular on T cell repertoire enhancement strategies. Simultaneously, I have begun to study the T cell repertoire in the setting of GVHD. Finally, I have also examined how aspects of mucosal immunology can impact on intestinal GVHD, including the microbial flora and dietary factors.
Publications by Robert R. Jenq
- Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao U, Yim N, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MRM. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses following murine allogeneic bone marrow transplantation. Blood. 2009 Feb 12;113(7):1574-80.
- Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010 Mar;10(3):213-21.
- Jenq RR*, Curran MA*, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLoS One. 2012;7(4):e35222. Epub 2012 Apr 6.
- Jenq RR*, Ubeda C*, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh A, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MR. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012 May 7;209(5):903-11. Epub 2012 Apr 30.
My career aim is to develop and evaluate strategies that improve outcomes after hematopoietic stem cell transplantation (HSCT), in particular by augmenting graft-versus-tumor (GVT) to reduce the rates of malignant relapse and alleviating graft-versus-host disease (GVHD). To this goal, I have studied therapies that modulate alloreactive T cells in GVT and GVHD, using mouse models of HSCT.
To develop strategies of augmenting anti-tumor immunity following HSCT, I have focused in particular on T cell repertoire enhancement strategies. Simultaneously, I have begun to study the T cell repertoire in the setting of GVHD. Finally, I have also examined how aspects of mucosal immunology can impact on intestinal GVHD, including the microbial flora and dietary factors.
- Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao U, Yim N, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MRM. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses following murine allogeneic bone marrow transplantation. Blood. 2009 Feb 12;113(7):1574-80.
- Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010 Mar;10(3):213-21.
- Jenq RR*, Curran MA*, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLoS One. 2012;7(4):e35222. Epub 2012 Apr 6.
- Jenq RR*, Ubeda C*, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh A, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MR. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012 May 7;209(5):903-11. Epub 2012 Apr 30.
